Drug intelligence / Profile preview

rDEN1Δ30

Development stage: Phase 1
Lead developer: National Institute of Allergy and Infectious Diseases
Modality: Live Attenuated Vaccines → Live Vaccines → Prophylactic Vaccines → Vaccines & Immunotherapeutics
Administration: Subcutaneous

Overview

rDEN1Δ30 is a live attenuated investigational vaccine developed for the prevention of dengue virus serotype 1 (DENV-1) illness. It is administered subcutaneously and has demonstrated a promising safety and immunogenicity profile in clinical trials. A single dose of rDEN1Δ30 has been shown to be well-tolerated, with the ability to infect and induce seroconversion in the majority of vaccinees. The vaccine appears to induce sterilizing humoral immunity for at least six months following primary vaccination.

Other names: Dengue virus type 1 live-attenuated vaccine candidaterDEN1-∆30DEN1delta30DEN-1delta30DEN 1delta30

Beyond the preview

Go deeper on rDEN1Δ30.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on rDEN1Δ30.

Explore the full profile